Full Press Release Details
Appoints Andrew Singer to its Board of Directors
Nes-Ziona, Israel, April 17, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics
Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced the
appointment of Andrew Singer to its Board of Directors. Mr. Singer brings more than 25 years of experience in biotechnology, corporate
finance, mergers and acquisitions, and business strategy from his extensive investment banking and executive management career.
an honor to join the Enlivex Board at this important juncture in the Company's evolution," said Mr. Singer. "Enlivex
has developed a novel and exciting approach to reprogramming macrophages, with potential application across a range of autoimmune, inflammatory
and oncology indications. I look forward to collaborating with my fellow Board members and the Company's management team as we
work to advance Allocetra's clinical development. With a broad technology platform underpinned by strong science and multiple clinical
programs, I believe that Enlivex is well positioned for sustained success."
Shai Novik, Executive
Chairman of the Board of Enlivex, stated, "As a senior investment banker in the United States for several decades, Andrew has helped
many successful biotech companies craft and execute their corporate and financial strategy. Additionally, Andrew has hands-on experience
as a public biotech company executive, leading finance and business development, having executed and managed public financings as well
as partnerships with some of the world's leading pharmaceutical companies. We believe that Andrew's extensive experience
makes him an ideal fit for Enlivex's Board. We look forward to benefiting from his expert insights as we execute on our clinical
and corporate strategy. It is my pleasure to welcome him to the Company as a board member."
determined that Mr. Singer is an "independent director" within the meaning of NASDAQ Listing Rule 5605(a)(2).
is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases
such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages
contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra has the
potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet
medical needs", as a stand-alone therapy or in combination with leading therapeutic agents.
is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra , a universal, off-the-shelf cell therapy
designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state
is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit https://enlivex.com/.
Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as "expects,"
"plans," "projects," "will," "may," "anticipates," "believes,"
"should," "would", "could," "intends," "estimates," "suggests,"
"has the potential to" and other words of similar meaning, including statements regarding expected cash balances, market
opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities
for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties
that may affect Enlivex's business and prospects, including the risks that Enlivex may not succeed in generating
any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or
effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied
or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties
that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in
humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage
trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product
line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional
time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive
products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition
to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other
factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's
most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained
in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.